{
  "source": "PA-Notification-Apokyn.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1344-5\nProgram Prior Authorization/Notification\nMedication Apokyn® (apomorphine) injection\nP&T Approval Date 12/2020, 12/2021, 12/2022, 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nApokyn is a non-ergoline dopamine agonist indicated for the acute, intermittent treatment of\nhypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off”\nepisodes) associated with advanced Parkinson’s disease.\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Apokyn will be approved based on both of the following:\na. Diagnosis of Parkinson’s disease\n-AND-\nb. Used as intermittent treatment for OFF episodes\nAuthorization will be issued for 6 months.\nB. Reauthorization\n1. Apokyn will be approved based on the following criteria:\na. Documentation of positive clinical response to Apokyn therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n© 2024 UnitedHealthcare Services, Inc.\n1\n• Supply limits and/or Medical Necessity may be in place.\n4. References:\n1. Apokyn [package insert]. Rockville, MD: MDD US Operations, LLC; June 2022.\nProgram Prior Authorization/Notification - Apokyn (apomorphine) injection\nChange Control\n12/2020 New program\n12/2021 Annual review with no changes.\n12/2022 Annual review with no changes to clinical coverage criteria. Added\nstate mandate footnote and updated reference.\n12/2023 Annu",
    "Control\n12/2020 New program\n12/2021 Annual review with no changes.\n12/2022 Annual review with no changes to clinical coverage criteria. Added\nstate mandate footnote and updated reference.\n12/2023 Annual review with no changes to coverage criteria.\n12/2024 Annual review with no changes to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}